Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term ...

⬆️ Bump actions/upload-artifact from 3 to 4 dependencies Pull requests that update a dependency file github_actions Pull requests that update GitHub Actions code ...

Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Official support for free-threaded Python, and free-threaded improvements Python’s free-threaded build promises true parallelism for threads in Python programs by removing the Global Interpreter Lock ...

When writing or testing Python scripts, your terminal can quickly become cluttered with logs, debug messages, and outputs. A clean console not only improves readability but also helps you stay focused ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

在编程世界中，命令行工具以其简洁、高效和跨平台的特性，成为开发者日常工作中不可或缺的一部分。无论是自动化脚本、系统管理工具，还是快速原型开发，一个优雅的命令行界面都能大幅提升用户体验。Python 作为一门通用编程语言，内置了 argparse 和 optparse 等库来构建命令行工具，但它们在复杂场景下显得繁琐。而 ...

Recent discussions on X about Replimune Group Inc. (REPL) have been ignited by the U.S. FDA's rejection of the company's lead drug, RP1, for melanoma treatment in combination therapy. Many users are ...